Skip to main content
. 2018 Feb;13(1):55–64. doi: 10.2174/1574884713666180518102514

Fig. (2).

Fig. (2)

Peripheral B-cell depletion in patients with relapsed/refractory NHL receiving blinatumomab at doses of ≥5 μg/m2/day. a Time profiles of Peripheral B-cell counts from 49 patients with detectable baseline B cells; the effect at different doses could not be distinguished. b Initial B-cell depletion rates as a function of Css after first dose (n=28) of first treatment period.